The Protein Lysine 6 Oxidase pipeline drugs market research report outlays comprehensive information on the Protein Lysine 6 Oxidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Protein Lysine 6 Oxidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Genito Urinary System, and Ophthalmology which include the indications Myelofibrosis, Pancreatic Ductal Adenocarcinoma, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Kidney Fibrosis, Myopia, and Keratoconus . It also reviews key players involved in Protein Lysine 6 Oxidase targeted therapeutics development with respective active and dormant or discontinued products.
The Protein Lysine 6 Oxidase pipeline targets constitutes close to nine molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 2, 2, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Protein Lysine 6 Oxidase overview
Protein lysine 6 oxidase (LOX) is an enzyme responsible for the post-translational oxidative deamination of peptidyl lysine residues in precursor molecules that give rise to fibrous collagen and elastin, which are key structural proteins in the body. In addition to its role in extracellular matrix formation, LOX is involved in other biological processes, including regulator of Ras expression, tumor suppression and aortic wall architecture.
For a complete picture of Protein Lysine 6 Oxidase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
